Nasdaq exas.

Exact Sciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 20th, 2024 based off last year's report dates. Learn more on EXAS's earnings history.Direct. 3,000. $16.52. 42,830. Back to EXAS Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC ...Our pipeline team is responsible for advancing our future tests and developing life-changing cancer diagnostics to help patients throughout the course of their diagnosis and treatment.3 Nov 2023 ... Exact Sciences Corporation [EXAS] Rings the Nasdaq Closing Bell | LIVE 07:29 Nasdaq MarketSite 3n #2.91% ЕХАСТ SCIENCES MAtaria Mvesday ...Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Web

Nov 20, 2023 · Kevin Conroy. https://www.exactsciences.com. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Nov 30, 2023

Nov 23, 2023 · EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ... Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.

Exact Sciences Corporation (NASDAQ:EXAS) is a leading global provider of cancer screening and diagnostic test products. On November 3, EXACT Sciences Corporation (NASDAQ:EXAS) announced earnings ...Shares of EXAS stock opened at $67.03 on Monday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.13 and a current ratio of 2.41. The firm has a market cap of $12.12 billion, a ...Nasdaq: EXAS · Russell 1000 component. Industry, Molecular diagnostics. Founded, 1995; 28 years ago (1995) in Marlborough, Massachusetts. Founders. Stanley ...Board. Exact Sciences to participate in November investor conferences. November 01 2023 - 06:00AM. PR Newswire (US) MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ...(Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of ...

Exact Sciences Corporation Common Stock ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.

Kevin Conroy. https://www.exactsciences.com. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

2 Nov 2023 ... ... Nasdaq MarketSIte · Trust Center · Newsletters · Chrome Extension · Privacy Policy · Cookies · Legal; Cookies Settings. © 2023, Nasdaq, Inc. All ...MADISON, Wis., Nov. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, 2022, compared to $456 million for the same period of 2021.Apr 7, 2023 · First on this list of millionaire-maker stocks is Exact Sciences (NASDAQ :EXAS ), an exciting company in the world of cancer research. Exact Sciences has developed one highly successful cancer ... Exact Sciences Corp (NASDAQ:EXAS) Exact Sciences Corp. 65.13. Delayed Data. As of Nov 21. -2.15 / -3.20%. Today’s Change. 40.73.WebExact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...Exact Sciences Co. (NASDAQ:EXAS – Free Report) – Analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for Exact Sciences in a research report issued to clients and investors on ...

Exact Sciences Corporation Common Stock (EXAS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...Fintel reports that on May 10, 2023, Craig-Hallum upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Hold to Buy.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the ...The company is scheduled to release Q3 earnings on November 3, 2022, after the market close. The market expects revenue of $503 million, a modest 10% YoY growth forecast. As EXAS starts shifting ...Shares of Exact Sciences ( EXAS 0.93%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ...

Nov 23, 2023 · EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ... NASDAQ: EXAS Exact Sciences. Market Cap. $12B. Today's Change (0.14%) $0.09. ... 10 stocks we like better than Exact Sciences When o ur analyst team has a stock tip, ...

Nasdaq | EXAS U.S.: Nasdaq Exact Sciences Corp. Watch NEW Set a price target alert Premarket Last Updated: Nov 30, 2023 7:29 a.m. EST Delayed quote $ 65.00 -0.06 -0.09% Before Hours Volume:...MADISON, Wis., Feb. 7, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced the launch of the OncoExTra ...EXASNASDAQ See on Supercharts Overview News Ideas Financials Technicals Forecast EXAS chart Today 4.73% 5 days 2.38% 1 month 9.53% 6 months −21.08% Year to date …WebExact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewha... Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last qu...Exact Sciences EXAS is the $19 billion leader in proactive cancer diagnostics with the Cologuard screening kit, ... anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -16.81%, and its shares gained 127.30% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...MADISON, Wis., Feb. 7, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced the launch of the OncoExTra ...See the latest Exact Sciences Corp stock price (EXAS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ...Find the latest analyst research for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ...

Exact Sciences Corp (EXAS) latest news, insider trading and hedge fund ownership data provided by Insider Monkey. ... Exact Sciences Corporation (NASDAQ:EXAS) Q3 2023 Earnings Call Transcript.

One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ...Find the latest SEC Filings data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Exact Sciences Corp ( NASDAQ:EXAS) is working on the development of additional tests, with the goal of bringing new, innovative cancer tests to patients worldwide. The company has reported a net ...Exact Sciences Co. (NASDAQ:EXAS) Insider Sells $864,835.43 in Stock marketbeat.com - October 13 at 8:39 PM: Baillie Gifford & Co. Sells 215,265 Shares of Exact Sciences Co. (NASDAQ:EXAS) marketbeat.com - October 12 at 3:16 PM: Exact Sciences upgraded at Piper Sandler on compelling entry point seekingalpha.com - October 12 at …Discover historical prices for EXAS stock on Yahoo Finance. View daily, weekly or monthly format back to when Exact Sciences Corporation stock was issued. ... Nasdaq 14,158.41-100.08 (-0.70% ...NASDAQ: EXACT Sciences Corporation (EXAS) = 65.06 USD. Provided by Alpha Vantage. EXACT Sciences Corporation stock (EXAS) in USD. 1 EXAS = 65.06 USD. 1 month. 6 months. 1 year. 5 years. Hold over 40 currencies to convert and send money at any time. Open an account.Exact Sciences (NASDAQ:EXAS – Get Free Report) last issued its quarterly earnings results on Tuesday, August 1st.The medical research company reported ($0.45) EPS for the quarter, beating ...Formed in 1995, Exact Sciences ( NASDAQ: EXAS) is a cancer screening and diagnostics company with the aim of early detection and improving cancer treatment. Currently, the company caters to ...Exact Sciences (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, visits the Nasdaq MarketSite in Times Square. In honor of the occasion, Kevin Conroy, Chairman & CEO ...Exact Sciences Corporation (NASDAQ:EXAS) Q2 2023 Earnings Call Transcript August 1, 2023 Exact Sciences Corporation beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.51.Find the latest news headlines from Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.

... Back to EXAS Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following …WebMay 18, 2023 · On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ... EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...Instagram:https://instagram. pfizer blue pillautozone stockswhere can i short stocksmpw Exact Sciences Co. (NASDAQ:EXAS – Free Report) – Analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for Exact Sciences in a research report issued to clients and investors on ...Kevin Conroy. https://www.exactsciences.com. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. liberty 1804 coinnike in china Exact Sciences Corporation Common Stock (EXAS) Nasdaq Listed; ... Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.MADISON, Wis., May 27, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced new data supporting its cancer tests and treatment ... sandp and dow Apr 10, 2023 · Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ... Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...Nov 22, 2023 · According to the issued ratings of 16 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 4 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $96.56 with a high price target of $130.00 and a low price target of $73.00.